Europe Genetic Testing Market Size and Forecast 2025–2033

Europe Genetic Testing Market Overview

Genetic testing refers to a broad range of medical tests used to analyze DNA, RNA, chromosomes, genes, or proteins to identify inherited traits, mutations, or predispositions to disease. These tests play a crucial role in predicting disease risk, confirming diagnoses, guiding treatment decisions, and supporting family planning. Samples are typically collected from blood, saliva, or tissue, and the testing process is often accompanied by genetic counseling due to the ethical, psychological, and privacy implications involved.

The Europe Genetic Testing Market is experiencing strong and sustained growth as genetic technologies become an integral part of modern healthcare. According to Renub Research, the market is expected to reach US$ 12.50 billion by 2033, rising from US$ 6.20 billion in 2024, registering a CAGR of 8.10% from 2025 to 2033.

Download Free Sample Report

This expansion is driven by a combination of factors, including the rising prevalence of genetic and chronic diseases, an aging population, rapid advancements in testing technologies, growing public awareness, and increased adoption of personalized medicine. Across Europe, genetic testing is increasingly being incorporated into routine diagnostics for oncology, rare diseases, prenatal screening, and pharmacogenomics.

Countries such as Germany, France, and the United Kingdom are at the forefront of this growth, supported by strong healthcare infrastructure, favorable government initiatives, and active research ecosystems. Meanwhile, the expansion of direct-to-consumer (DTC) genetic testing has also fueled public interest, making genetic insights more accessible than ever. Despite this progress, challenges such as high costs, regulatory complexity, and data privacy concerns continue to shape market dynamics.

Europe Genetic Testing Market Size and Forecast (2025–2033)

Europe Genetic Testing Market is expected to reach US$ 12.50 billion by 2033 from US$ 6.20 billion in 2024, with a CAGR of 8.10% from 2025 to 2033.

The market’s expansion reflects a broader shift toward precision healthcare, where genetic insights are used to tailor prevention strategies, diagnostics, and treatments at an individual level. As testing becomes faster, more accurate, and cost-effective, adoption across hospitals, diagnostic laboratories, and research institutions is expected to accelerate further.

Growth Drivers of the Europe Genetic Testing Market

Rising Incidence of Chronic and Hereditary Diseases

One of the most significant drivers of the European genetic testing market is the increasing prevalence of chronic illnesses and inherited disorders. Genetic testing plays a critical role in early diagnosis, risk assessment, and targeted treatment, particularly in oncology.

According to the European Cancer Information System, Europe is projected to record 3.13 million new cancer cases by 2035, rising further by 2040. As cancer incidence grows, the demand for genetic testing—especially for identifying inherited mutations and selecting targeted therapies—is expected to surge.

Beyond cancer, genetic testing is increasingly used for cardiovascular diseases, rare genetic disorders, and metabolic conditions, enabling early intervention and improved patient outcomes.

Growing Public Awareness and Preventive Healthcare Focus

Public awareness regarding genetic health risks has increased significantly across Europe. Media coverage, educational campaigns, and expanding access to DTC genetic testing services have empowered individuals to take a proactive approach to their health.

Consumers are increasingly seeking insights into disease predisposition, carrier status, and lifestyle-related genetic traits. This trend aligns with the broader movement toward preventive healthcare and wellness, where early detection and personalized risk management are prioritized.

Younger, technologically savvy populations—particularly in Western Europe—are driving adoption, contributing to wider acceptance of genetic testing beyond traditional clinical settings.

Advancements in Genetic Testing Technologies

Technological innovation remains a cornerstone of market growth. Breakthroughs such as next-generation sequencing (NGS), polymerase chain reaction (PCR) enhancements, microarrays, and AI-driven data analysis have transformed genetic testing. These technologies have reduced testing time, improved accuracy, and lowered costs, making advanced diagnostics more accessible.

In August 2022, Myriad Genetics expanded its MyChoice CDx Plus Testing services in Germany and France through partnerships with Institut für Hämopathologie Hamburg and Centre Georges-François Leclerc. Such collaborations highlight how technological progress and strategic alliances are expanding the reach of genetic testing across Europe.

Challenges Facing the Europe Genetic Testing Market

High Cost of Advanced Genetic Testing

Despite technological progress, the high cost of advanced genetic tests—such as whole-genome and whole-exome sequencing—remains a key challenge. Reimbursement policies vary significantly across European countries, limiting patient access in certain regions.

Healthcare providers and diagnostic laboratories often face budget constraints, while patients may delay or avoid testing due to out-of-pocket expenses. These cost barriers contribute to disparities in access and slow the widespread adoption of advanced genetic technologies.

Regulatory and Data Privacy Complexity

Europe’s regulatory environment presents another major challenge. While frameworks such as the General Data Protection Regulation (GDPR) and the In Vitro Diagnostic Regulation (IVDR) provide overarching guidance, individual countries maintain distinct healthcare regulations and approval processes.

This fragmented landscape increases compliance costs, delays market entry, and complicates cross-border expansion for genetic testing companies. Additionally, concerns about data privacy and ethical use of genetic information continue to influence public trust and regulatory scrutiny.

Country-Level Insights

France Genetic Testing Market

France’s genetic testing market is expanding steadily, supported by government-led initiatives and strong research infrastructure. The “Genomic Medicine France 2025” program aims to integrate genomic sequencing into routine care, particularly for cancer and rare diseases.

Technological advances in NGS and increased focus on preventive healthcare have driven demand across prenatal screening, oncology, and inherited disorders. While data privacy and reimbursement challenges persist, France is emerging as a key innovation hub in Europe’s genetic testing landscape.

Germany Genetic Testing Market

Germany represents one of the largest genetic testing markets in Europe, driven by a robust healthcare system, strong funding for genomic research, and growing awareness of personalized medicine.

In February 2022, Genetic Analysis AS, in collaboration with the Institut für Medizinische Diagnostik, introduced the GA-map Dysbiosis Test in Germany, expanding standardized microbiome testing. Additionally, partnerships such as the Blueprint Genetics–BioMarin sponsored testing program for skeletal dysplasia have enhanced accessibility and market reach.

With increasing applications in oncology, prenatal care, and rare diseases, Germany is expected to maintain strong growth throughout the forecast period.

United Kingdom Genetic Testing Market

The UK genetic testing market has witnessed rapid expansion, supported by strong government initiatives and the integration of genomics into the National Health Service (NHS).

In October 2022, NHS England launched a nationwide genetic testing program enabling rapid diagnosis of life-threatening genetic conditions in infants and children. The program supports early treatment for over 6,000 genetic disorders, significantly improving patient outcomes.

Continued investments in genomic research, coupled with rising adoption in cancer and prenatal diagnostics, position the UK as a leader in genetic testing adoption.

Spain Genetic Testing Market

Spain’s genetic testing market is growing steadily due to increased government investment in healthcare infrastructure and genomic research. Advances in NGS technology have improved testing accuracy and affordability, driving adoption in oncology, neonatal screening, and rare disease diagnostics.

The growing popularity of DTC genetic testing is also expanding access among the general population, reinforcing Spain’s role as an emerging growth market in Southern Europe.

Market Segmentation Overview

By Type

Predictive Testing

Carrier Testing

Prenatal and Newborn Testing

Diagnostic Testing

Pharmacogenomic Testing

Nutrigenomic Testing

Others

By Product

Consumables

Equipments

Software & Services

By Technology

PCR

DNA Sequencing

Microarrays

Others

By Disease

Cancer

Genetic Diseases

Cardiovascular Diseases

Rare Diseases

Infectious Diseases

Others

By End User

Hospitals & Clinics

Diagnostic Laboratories

Others

By Country

France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Russia, Poland, Greece, Norway, Romania, Portugal, and Rest of Europe.

Key Players Analysis

The European genetic testing market is highly competitive, with global and regional players focusing on innovation, partnerships, and geographic expansion. All companies are analyzed across four dimensions: company overview, key persons, recent developments & strategies, and sales analysis.

Key Market Players Include:

Abbott Laboratories

Danaher Corporation (Cepheid Inc.)

Illumina Inc.

Bio-Rad Laboratories Inc.

F. Hoffmann-La Roche AG

DiaSorin

Revvity Inc.

Thermo Fisher Scientific Inc.

These companies continue to invest in advanced technologies, expand test portfolios, and collaborate with healthcare institutions to strengthen their European presence.

Final Thoughts

The Europe Genetic Testing Market is entering a transformative phase, driven by technological innovation, rising disease burden, and a growing emphasis on personalized medicine. With the market projected to grow from US$ 6.20 billion in 2024 to US$ 12.50 billion by 2033, genetic testing is set to become a cornerstone of modern European healthcare.

While challenges related to cost, regulation, and data privacy remain, ongoing government support, research investments, and public awareness initiatives are expected to offset these barriers. As genetic insights increasingly guide diagnosis, treatment, and prevention, Europe’s genetic testing market will play a pivotal role in shaping the future of precision healthcare.